As interest in the future of interventional psychiatry continues to grow, new data are helping researchers better understand how psychedelic substances are being used outside clinical settings. A recently published national analysis provides one of the most comprehensive looks to date at psilocybin use across the United States, offering important insights for clinicians, researchers, and policymakers.
Psilocybin, the psychoactive compound found in certain mushroom species, has become a major focus of psychedelic research. Clinical studies have explored its potential role in treating depression, anxiety, substance use disorders, and other psychiatric conditions. At the same time, public interest has expanded alongside decriminalization efforts and growing media attention.
Growing Interest Outpaces Existing Surveillance
Despite increasing discussion about psychedelic therapies, surprisingly little was known about how many Americans were actually using psilocybin. Previous national surveys did not specifically ask participants about psilocybin use, limiting researchers’ ability to track prevalence and identify demographic patterns.
That changed with the 2024 National Survey on Drug Use and Health, the first survey cycle to include specific questions about psilocybin. Researchers analyzed responses from more than 58,000 participants aged 12 years and older to estimate national usage patterns.
The findings suggest that psilocybin use has become more widespread than many experts anticipated.
What The Psilocybin Use Trends Data Revealed
Researchers found that 2.8% of survey participants reported using psilocybin during the previous year. When projected to the broader U.S. population, this represents approximately 8 million individuals.
Young adults were among the most likely users. Individuals between ages 18 and 25 demonstrated significantly higher odds of psilocybin use compared to adults aged 35 to 49 years.
Gender differences were also apparent. Men reported psilocybin use more frequently than women, while adults aged 50 years and older were substantially less likely to report recent use.
The analysis identified educational and socioeconomic patterns as well. Individuals with some college education or advanced degrees were more likely to report psilocybin use than those without a high school diploma.
Depression And Substance Use Connections
One of the most clinically relevant findings involved mental health status. Individuals who reported experiencing depression during the previous year showed elevated odds of psilocybin use compared with those who did not report depression.
Researchers also observed strong associations between psilocybin use and other substances. Cannabis users were far more likely to report psilocybin use, while elevated rates were also observed among individuals who reported using LSD, ketamine, MDMA, cocaine, or prescription stimulants.
These findings do not establish cause and effect. The survey design cannot determine whether mental health symptoms influenced psilocybin use, whether psilocybin use affected mental health outcomes, or whether both are influenced by other factors.
However, the results suggest that clinicians may increasingly encounter patients who are experimenting with psychedelic substances while also managing psychiatric symptoms.
Why These Findings Matter For Clinical Practice
The growing prevalence of psilocybin use creates new considerations for psychiatric assessment and treatment planning.
As psychedelic therapies move through clinical development pipelines, more individuals may seek information about psilocybin from healthcare providers. Understanding who is using these substances and how usage patterns intersect with depression and other substance use behaviors can help clinicians have more informed conversations with patients.
The findings also highlight the importance of distinguishing between recreational, self-directed, and medically supervised psychedelic experiences. Clinical trials involving psilocybin typically include extensive screening, psychological support, controlled dosing protocols, and structured follow-up care.
These safeguards differ substantially from real-world, unsupervised use.
A New Baseline For Future Research
Perhaps the most important contribution of this study is the establishment of a national benchmark. Researchers now have a clearer picture of current psilocybin use trends as regulatory discussions and clinical research continue to evolve.
Future surveys will help determine whether prevalence continues to rise and whether demographic patterns shift as public awareness grows. Additional research may also clarify why individuals with depression appear more likely to report psilocybin use and how those decisions relate to treatment seeking and mental health outcomes.
For the field of interventional psychiatry, these findings underscore the importance of continued surveillance, evidence-based guidance, and careful clinical evaluation as psychedelic therapies increasingly intersect with mainstream psychiatric care.
Citations
Yang KH, Eun A, Palamar JJ. “Prevalence and Correlates of Past-Year Psilocybin Use in the United States.” The American Journal of Psychiatry (2026). https://doi.org/10.1176/appi.ajp.20250595
Substance Abuse and Mental Health Services Administration. “2024 NSDUH Annual National Report.” https://www.samhsa.gov/data/report/2024-nsduh-annual-national-report
Explore more at https://www.interventionalpsychiatry.org/